At the same time, among the three BC99 groups, only the activity of CYP2E1 in the high-dose group was significantly different from that in the AD group (p < 0.01), and compared with the AD group, the activity of CYP2E1 decreased by 16.84%. This evidence concerns the gene CYP2E1 and Alzheimer disease.